1-14 of 14
Anik R Patel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment Patterns and Predictors of Survival after First Line Therapy in Large B-Cell Lymphoma in a Real-World US Cohort

Joseph P. McGuirk, Mark Fesen, Scott D. Ramsey, Rony Abou-Jawde, Anthony Proli, Hil Hsu, Anik R Patel, Miguel-Angel Perales, Blythe Adamson, Jiarui Fu, Jeremy Snider
Journal: Blood
Blood (2024) 144 (Supplement 1): 2367.
https://doi.org/10.1182/blood-2024-208283
Published: 2024
Journal Articles

Real-World Interim PET/CT Scan Use during Frontline (1L) Therapy and Subsequent Treatment Characteristics in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Ran Reshef, Constance Lau, Hil Hsu, Brett Doble, Clare Spooner, Anik R Patel, Liana Nikolaenko
Journal: Blood
Blood (2024) 144 (Supplement 1): 7775.
https://doi.org/10.1182/blood-2024-200288
Published: 2024
Journal Articles

Physician Treatment Preferences in Relapsed/Refractory Follicular Lymphoma: A Discrete Choice Experiment

John G. Gribben, Emmanuel Bachy, Markqayne Ray, Kathryn Krupsky, Kathleen Beusterien, Lewis Kopenhafer, Flor Mendez, Sara Beygi, Timothy Best, Graeme Ball, Kacper Perkowski, Patrick Olsen, Anik R Patel, Paola Ghione
Journal: Blood
Blood (2023) 142 (Supplement 1): 4424.
https://doi.org/10.1182/blood-2023-190261
Published: 2023
Journal Articles

Statistical Challenges from Trials of Potentially Curative Treatments: Validation of Cure Assumptions When Analyzing Zuma-7 Follow-up Data of Axi-Cel and Standard of Care Therapy

Anik R Patel, Mark Ray, Yael A Rodriguez-Guadarrama, Nathaniel J Smith, Frank Neumann, Rob Blisset, Allen Xiaodong Xue
Journal: Blood
Blood (2023) 142 (Supplement 1): 6899.
https://doi.org/10.1182/blood-2023-181255
Published: 2023
Journal Articles

Cost-Effectiveness of Axicabtagene Ciloleucel Versus Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma in the US

Olalekan O. Oluwole, Markqayne D Ray, Richard Zur, Aurelia Little, Cheryl Ferrufino, Brett Doble, Anik R Patel, Pinar Bilir
Journal: Blood
Blood (2023) 142 (Supplement 1): 5082.
https://doi.org/10.1182/blood-2023-186548
Published: 2023
Journal Articles

An Updated Comparison of Clinical Outcomes from 4-Year Follow-up of Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma

John G. Gribben, Paola Ghione, Maria Lia Palomba, Markqayne D Ray, Eve H Limbrick-Oldfield, Steve Kanters, Sabela Bobillo, Maria Teresa Ribiero, Caron A Jacobson, Sattva S. Neelapu, Herve Ghesquieres, Olga Nikolajeva, Jiali Yan, Hailin Wang, Anik R Patel
Journal: Blood
Blood (2023) 142 (Supplement 1): 4869.
https://doi.org/10.1182/blood-2023-186842
Published: 2023
Journal Articles

Network Meta-Analysis (NMA) of Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) after 2 Prior Treatments Using Published Comparative Studies

Frederick L. Locke, Sattva S. Neelapu, Markqayne D. Ray, Eve H Limbrick-Oldfield, Sally W Wade, Steve Kanters, Anik R. Patel, Olalekan O. Oluwole
Journal: Blood
Blood (2022) 140 (Supplement 1): 7516–7518.
https://doi.org/10.1182/blood-2022-169812
Published: 2022
Journal Articles

Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel

Frederick L. Locke, Zhen-Huan Hu, Tanya Siddiqi, Caron A. Jacobson, Sarah Nikiforow, Sairah Ahmed, David B. Miklos, Yi Lin, Matthew A. Lunning, Brian T. Hill, Armin Ghobadi, Harry Miao, Shilpa Shahani, Clare Spooner, Christine Fu, Anik R. Patel, Hairong Xu, Marcelo C Pasquini
Journal: Blood
Blood (2022) 140 (Supplement 1): 7512–7515.
https://doi.org/10.1182/blood-2022-155603
Published: 2022
Journal Articles

Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients with Relapsed or Refractory Follicular Lymphoma in the United States

Olalekan O. Oluwole, Markqayne D. Ray, Katherine L. Rosettie, Graeme Ball, Jorge Jacob, Pinar Bilir, Anik R. Patel, Caron A. Jacobson
Journal: Blood
Blood (2022) 140 (Supplement 1): 10822–10824.
https://doi.org/10.1182/blood-2022-163789
Published: 2022
Journal Articles

A 3-Year Follow-up Comparison of Clinical Outcomes from Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)

Paola Ghione, Maria Lia Palomba, Markqayne D. Ray, Eve H. Limbrick-Oldfield, Jess Owen, Steve Kanters, Sabela Bobillo, Maria Teresa Ribeiro, Caron A. Jacobson, Sattva S. Neelapu, Herve Ghesquieres, Myrna Nahas, Sara Beygi, Anik R. Patel, John G. Gribben
Journal: Blood
Blood (2022) 140 (Supplement 1): 4676–4677.
https://doi.org/10.1182/blood-2022-170469
Published: 2022
Journal Articles

Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy

Matthew A. Lunning, Hai-Lin Wang, Zhen-Huan Hu, Frederick L. Locke, Tanya Siddiqi, Caron A. Jacobson, Sairah Ahmed, David B. Miklos, Yi Lin, Brian T. Hill, Armin Ghobadi, Sattva S. Neelapu, Jason Westin, Harry Miao, Shilpa Shahani, Anik R. Patel, Clare Spooner, Christine Fu, Hairong Xu, Marcelo C Pasquini
Journal: Blood
Blood (2022) 140 (Supplement 1): 1852–1855.
https://doi.org/10.1182/blood-2022-162421
Published: 2022
Journal Articles

Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma

Clinical Trials & Observations
Paola Ghione, M. Lia Palomba, Anik R. Patel, Sabela Bobillo, Kevin Deighton, Caron A. Jacobson, Myrna Nahas, Anthony J. Hatswell, A. Scott Jung, Steve Kanters, Julia Thornton Snider, Sattva S. Neelapu, Maria Teresa Ribeiro, M. Alan Brookhart, Herve Ghesquieres, John Radford, John G. Gribben
Journal: Blood
Blood (2022) 140 (8): 851–860.
https://doi.org/10.1182/blood.2021014375
Published: 2022
Includes: Supplemental data
Journal Articles

A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)

M. Lia Palomba, Paola Ghione, Anik R. Patel, Kevin Deighton, Caron Jacobson, Myrna Nahas, A Scott Jung, Anthony J Hatswell, Steve Kanters, Eve Limbrick-Oldfield, Sally W Wade, Julia Thornton Snider, Sattva S. Neelapu, Maria Teresa Riberio, John Gribben, John Radford, Sabela Bobillo, Herve Ghesquieres
Journal: Blood
Blood (2021) 138 (Supplement 1): 3543.
https://doi.org/10.1182/blood-2021-147608
Published: 2021
Journal Articles

Efficacy Outcomes of Treatments for Double Relapsed/Refractory Follicular Lymphoma (R/R FL): A Systematic Literature Review

Brad S. Kahl, MD, Anik R. Patel, PhD, Omer Zaidi, Sonya J. Snedecor, PhD, Anna G. Purdum, PharmD,MS
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-136228
Published: 2020